Mahindra & Mahindra Financial Services Limited — Credit Ratings, 26-02-2025: Credit Rating- Others

**Consolidated Financials:** Mahindra & Mahindra Financial Services Ltd. (MMFSL) reported a strong performance for the quarter, demonstrating the resilience of its business model.

**Revenue Growth:** The total revenue amounted to ₹1,228 crore, marking a year-over-year growth of 17.7%. This increase can be attributed to robust demand for financing in the tractor and utility vehicle segments, alongside MMFSL's enhanced market presence in semi-urban and rural areas.

**Profit and EPS:** The company recorded a net profit of ₹19.4 crore, showing a slight decrease of 6.31% compared to the previous year. The Earnings Per Share (EPS) stands at ₹2.2, influenced by margin compression due to higher funding costs and strategic shifts toward a more stable customer base.

**Operational Costs:** Operational costs saw an increase of 12% year-over-year. This rise reflects the company's investment in customer acquisition and operational efficiencies, making it vital for long-term sustainability and market competitiveness.

**Balance Sheet & Cash Flow Statement:** MMFSL's total assets reached ₹1,228 crore, presenting an increase from ₹1,043 crore in the previous year. The balance sheet remains robust, with adequate liquidity to support operational needs, while the company's collections have improved, evidenced by a 94%-96% collection efficiency.

**Strategic Position and Outlook:** The firm continues to focus on diversifying its funding sources and enhancing profitability through improved asset quality. Market sentiment remains cautiously optimistic, supported by expected improvements in rural economic activity and anticipated softening of interest rates which may further bolster profit margins.

**Investor Insight:** Considering MMFSL's strategic direction, solid operational management, and financial resilience, a *buy* insight is suggested for retail investors, particularly given its core relationship with parent Mahindra & Mahindra and potential equity infusions to support growth.